ATE429504T1 - Proteinexpressionsvektor und benutzung desselbigen - Google Patents

Proteinexpressionsvektor und benutzung desselbigen

Info

Publication number
ATE429504T1
ATE429504T1 AT99972690T AT99972690T ATE429504T1 AT E429504 T1 ATE429504 T1 AT E429504T1 AT 99972690 T AT99972690 T AT 99972690T AT 99972690 T AT99972690 T AT 99972690T AT E429504 T1 ATE429504 T1 AT E429504T1
Authority
AT
Austria
Prior art keywords
expression vector
nucleotide sequence
protein expression
downstream side
cloning site
Prior art date
Application number
AT99972690T
Other languages
English (en)
Inventor
Hidetoshi Uemura
Akira Okui
Katsuya Kominami
Nozomi - Yamaguchi
Shinichi Mitsui
Original Assignee
Fuso Pharmaceutical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Ind filed Critical Fuso Pharmaceutical Ind
Application granted granted Critical
Publication of ATE429504T1 publication Critical patent/ATE429504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99972690T 1998-11-20 1999-11-19 Proteinexpressionsvektor und benutzung desselbigen ATE429504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33151598 1998-11-20
PCT/JP1999/006474 WO2000031284A1 (en) 1998-11-20 1999-11-19 Protein expression vector and utilization thereof

Publications (1)

Publication Number Publication Date
ATE429504T1 true ATE429504T1 (de) 2009-05-15

Family

ID=18244518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972690T ATE429504T1 (de) 1998-11-20 1999-11-19 Proteinexpressionsvektor und benutzung desselbigen

Country Status (8)

Country Link
US (1) US7029909B1 (de)
EP (1) EP1132479B1 (de)
JP (1) JP4475814B2 (de)
AT (1) ATE429504T1 (de)
AU (1) AU765111B2 (de)
CA (1) CA2350226C (de)
DE (1) DE69940785D1 (de)
WO (1) WO2000031284A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061064A2 (de) * 2001-02-01 2002-08-08 Roche Diagnostics Gmbh Verfahren zur herstellung von rekombinantem trypsin
WO2003038049A2 (en) 2001-10-29 2003-05-08 Renovis, Inc. Method for isolating cell-type specific mrnas
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
JP2006345831A (ja) * 2005-06-20 2006-12-28 P-Lap:Kk Ｄｎａ、ベクター、形質転換体、及びａｐａタンパク質の製造方法
JP5130662B2 (ja) * 2006-06-07 2013-01-30 Ｊｎｃ株式会社 タンパク質の可溶性タンパク質としての製造方法
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
TW200833840A (en) 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
EP2738257A1 (de) 2007-05-22 2014-06-04 Amgen Inc. Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
JP5670755B2 (ja) 2008-03-12 2015-02-18 ザ ロックフェラー ユニバーシティ 翻訳プロファイリング及び分子表現型解析のための方法及び組成物
JP2012521360A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
WO2012021648A1 (en) 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
EP2725034B1 (de) 2010-09-22 2019-04-03 Amgen Inc. Trägerimmunglobuline die nicht an humane Gewebe binden und Verwendungen davon
WO2012076715A1 (en) 2010-12-09 2012-06-14 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
US20150201588A1 (en) 2012-02-22 2015-07-23 Amgen Inc. Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
EP3039129B1 (de) 2013-08-30 2018-06-27 Amgen Inc. Herstellung rekombinanter aav-vektoren mit hohem titer in haftenden und hängenden zellen
US9822156B2 (en) 2014-06-13 2017-11-21 Whitehead Institute For Biomedical Research Amyloid beta expression constructs and uses therefor
EP3206707B1 (de) 2014-10-13 2020-12-02 University of Maryland, Baltimore Fc-ela-32 und deren verwendung zur behandlung von herzerkrankungen
JP6749898B2 (ja) 2014-10-15 2020-09-02 アムジエン・インコーポレーテツド 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
KR101787485B1 (ko) * 2015-12-30 2017-11-15 재단법인 의약바이오컨버젼스연구단 재조합 picp 단백질 및 이에 특이적으로 결합하는 항체의 제조방법
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
US20220119757A1 (en) 2019-02-15 2022-04-21 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
US20240318114A1 (en) 2021-07-15 2024-09-26 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
AU2023219515A1 (en) 2022-02-10 2024-08-08 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
CN118580307B (zh) * 2024-05-21 2025-05-27 广东合鸣生物科技有限公司 一种具备紧致抗皱功效的Pro.AH8乙酰基六肽-8及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3582965B2 (ja) * 1996-08-23 2004-10-27 株式会社イムノ・ジャパン 哺乳動物細胞用発現ベクター

Also Published As

Publication number Publication date
EP1132479B1 (de) 2009-04-22
DE69940785D1 (de) 2009-06-04
WO2000031284A1 (en) 2000-06-02
CA2350226C (en) 2012-04-24
JP4475814B2 (ja) 2010-06-09
US7029909B1 (en) 2006-04-18
AU765111B2 (en) 2003-09-11
EP1132479A4 (de) 2005-08-10
EP1132479A1 (de) 2001-09-12
CA2350226A1 (en) 2000-06-02
AU1184000A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
ATE429504T1 (de) Proteinexpressionsvektor und benutzung desselbigen
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
NO20034959D0 (no) Anti-frys konsentrat inneholdende fargestoffer C.I. reactive violet 5
DE69836588D1 (de) Tuberkulose impfstoff
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
IT1268332B1 (it) Dispositivo manipolatore per la movimentazione, in particolare per l'orientamento di pezzi, utensili, o simili.
DE69934415D1 (de) Neuartiges collectin
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
EA200000567A1 (ru) Бактериальные плазмиды
ATE307940T1 (de) Putzleiste aus kunststoff
ITTO20010850A0 (it) Apparecchiatura di comando per l'iniezione di carburante.
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
DE69421665D1 (de) Anomere Fluorribosylamine
IL136496A0 (en) Nucleotide sequences encoding the tomato light hypersensitive phenotype, encoded proteins and uses thereof
ATE283356T1 (de) Tab1 protein und dafür kodierende dna
ITTO20010545A0 (it) Apparecchiatura di controllo dell'iniezione di carburante.
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
FR2710113B1 (fr) Barreau magnétique courbe ou rectiligne, formé d'aimants disjoints.
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
WO2002022822A3 (en) Plant derived bag homologues
Deutsch et al. Erratum: Interaction Physics of the Fast Ignitor Concept [Phys. Rev. Lett. 77, 2483 (1996)]
NL1012028A1 (nl) Aminozuursequentie.
ITMI920320A1 (it) Composizione marcante-denaturante particolarmente adatta per marcare e denaturare bitumi combustibili o prodotti affini.
ATE409747T1 (de) Mit wt1 interagierendes protein, wtip

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties